Interferon Alfacon-1

CHEMBL1201557 Phase 4 已批准 Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This synthetic consensus interferon is used to treat chronic hepatitis C by boosting antiviral immune responses and directly inhibiting viral replication. It was designed by identifying the most common amino acid at each position across multiple natural interferon subtypes. It is given by subcutaneous injection, typically with close monitoring of blood counts and mental health.

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This synthetic consensus interferon is used to treat chronic hepatitis C by boosting antiviral immune responses and directly inhibiting viral replication. It was designed by identifying the most common amino acid at each position across multiple natural interferon subtypes. It is given by subcutaneous injection, typically with close monitoring of blood counts and mental health.

Yes, Interferon Alfacon-1 is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201557. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.